The Technical Analyst
NeuBase Therapeutics Inc [NBSE]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
NeuBase Therapeutics Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
1.32% $0.430
America/New_York / 19 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 1.613 mill |
| EPS: | -18.60 |
| P/E: | -0.0200 |
| Earnings Date: | Apr 18, 2024 |
| SharesOutstanding: | 3.75 mill |
| Avg Daily Volume: | 0.234 mill |
| RATING 2024-04-19 |
|---|
| B+ |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Strong Buy | |
| P/E: | Neutral | |
| Price To Book: | Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 2/22 | 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | n/a | ||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.0200 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0.00x |
| Company: PE -0.0200 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 0.320 - 0.540 ( +/- 25.58%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2022-12-31 | Symetryx Corp | Buy | 0 | |
| 2023-09-14 | Symetryx Corp | Sell | 129 108 | Common Stock, Par Value $0.0001 per Share |
| 2023-09-15 | Symetryx Corp | Sell | 103 337 | Common Stock, Par Value $0.0001 per Share |
| 2023-09-18 | Symetryx Corp | Sell | 50 000 | Common Stock, Par Value $0.0001 per Share |
| 2023-08-23 | Symetryx Corp | Sell | 0 | Common Stock, Par Value $0.0001 per Share |
| INSIDER POWER |
|---|
| -20.07 |
| Last 87 transactions |
| Buy: 13 371 397 | Sell: 4 577 643 |
Forecast:
16:00 - $0.430
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $0.430
Forecast 2: 16:00 - $0.430
Forecast 3: 16:00 - $0.430
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $0.430 (1.32% ) |
| Volume | 0.0888 mill |
| Avg. Vol. | 0.234 mill |
| % of Avg. Vol | 37.90 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For NBSE
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
NBSE
NeuBase Therapeutics, Inc., a pre-clinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders, and cancer and oncology applications. Its lead programs include NT0100, a PATrOL enabled anti-gene for Huntington's disease; NT0200, a PATrOL enabled anti-gene for myotonic dystrophy type 1; NT0300, a PATrOL-enabled therapeutic treatment to target the mutated KRAS gene. NeuBase Therapeutics, Inc. is headquartered in Pittsburgh, Pennsylvania.
Latest Press Releases
2024-04-05 16:05:00 - Press Release
Neubase Therapeutics Announces Receipt Of Notice From Nasdaq
Pittsburgh, april 05, 2024 (globe newswire) -- neubase therapeutics, inc. (nasdaq: nbse) (“neubase” or the “company”) today reported that it received a notice (the “notice) on april 4, 2024 from the listing qualifications department of the nasdaq stock market llc (“nasdaq”) notifying the company that it was not in compliance with nasdaq's continued listing requirements under nasdaq listing rule 5250(c)(1) (the “rule”) as a result of its failure to file its annual report on form 10-k for the fiscal year ended december 31, 2023 (the “form 10-k”) in a timely manner.
2023-09-08 07:00:00 - Press Release
Neubase Therapeutics Issues Statement Regarding Filing By Shareholder
Pittsburgh, sept. 08, 2023 (globe newswire) -- neubase therapeutics, inc. (nasdaq: nbse) (“neubase” or the “company”) today issued the following statement regarding the schedule 13d filed with the u.s. securities and exchange commission on august 31, 2023, by symetryx corporation (“symetryx”) and their subsequent press release issued on september 6, 2023.
2023-09-06 10:00:00 - Press Release
Symetryx Corporation Acquires 20% Stock In Neubase
Urges board to consider a $1 dividend toronto , sept. 6, 2023 /prnewswire/ - today, symetryx corporation ("symetryx") announced that it has acquired 20% of the issued and outstanding common stock in neubase therapeutics inc. (nasdaq: nbse) ("neubase").
2023-08-03 07:00:00 - Press Release
Neubase Therapeutics To Explore Strategic Alternatives
Pittsburgh, aug. 03, 2023 (globe newswire) -- neubase therapeutics, inc. (nasdaq: nbse) (“neubase” or the “company”), a biotechnology company developing stealth editors™ to perform in vivo gene editing without triggering the immune system, today announced that its board of directors (the “board”) has completed a review of the company's business, including the status of its programs, resources, and capabilities. the board has made the determination to halt further development of the company's programs and to conduct a comprehensive exploration of strategic alternatives focused on maximizing shareholder value.
2023-05-02 17:00:00 - Press Release
Neubase Therapeutics Selected To Present Two Oral Presentations At The American Society Of Gene & Cell Therapy (asgct) 2023 Annual Meeting
Pittsburgh, may 02, 2023 (globe newswire) -- neubase therapeutics, inc. (nasdaq: nbse) ("neubase" or the "company"), a biotechnology company developing stealth editors™ to perform in vivo gene editing without triggering the immune system, today announced two abstracts have been accepted for two oral presentations at the american society of gene & cell therapy (“asgct”) 26th annual meeting, which will take place in los angeles, ca and virtually on may 16-20, 2023.
Latest News
2024-03-26 09:08:10 - InvestorPlace
Why Is NeuBase Therapeutics (NBSE) Stock Down 58% Today?
NeuBase Therapeutics (NASDAQ: NBSE ) stock is falling on Tuesday after the company announced details for an upcoming special shareholder meeting. The big news here is that NeuBase Therapeutics is seeking shareholder approval for the liquidation and dissolution of the company.
2023-09-14 12:00:29 - PennyStocks
Cheap Penny Stocks To Buy Now? 3 For Your Watch List
Penny stocks remain an alluring yet high-risk asset class for many novice investors. With share prices under $5, penny stocks appear affordable but bring higher volatility.
2023-09-07 12:47:23 - Zacks Investment Research
NeuBase (NBSE) Surges 107% on New Shareholder Acquiring Stake
With NeuBase (NBSE) exploring strategic alternatives to the company, Symetryx joins the company's shareholder base and urges the board to issue a unique $1 per share dividend.
2023-09-06 08:04:33 - InvestorPlace
Why Is NeuBase Therapeutics (NBSE) Stock Up 19% Today?
NeuBase Therapeutics (NASDAQ: NBSE ) stock is taking off on Wednesday despite a lack of news from the preclinical biopharmaceutical company. There are no new press releases from NeuBase Therapeutics or filings with the Securities and Exchange Commission (SEC) that explain why the stock is up today.
2023-05-02 17:00:00 - GlobeNewsWire
NeuBase Therapeutics Selected to Present Two Oral Presentations at the American Society of Gene & Cell Therapy (ASGCT) 2023 Annual Meeting
PITTSBURGH, May 02, 2023 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) ("NeuBase" or the "Company"), a biotechnology company developing Stealth Editors™ to perform in vivo gene editing without triggering the immune system, today announced two abstracts have been accepted for two oral presentations at the American Society of Gene & Cell Therapy (“ASGCT”) 26th Annual Meeting, which will take place in Los Angeles, CA and virtually on May 16-20, 2023.
2023-01-20 13:32:31 - Zacks Investment Research
What Makes NeuBase (NBSE) a New Strong Buy Stock
NeuBase (NBSE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
2023-01-20 07:32:04 - Zacks Investment Research
New Strong Buy Stocks for January 20th
NBSE, PRTG, RELL, HOWL and PATH have been added to the Zacks Rank #1 (Strong Buy) List on January 20, 2022.
2022-12-27 11:13:54 - PennyStocks
Best Penny Stocks To Buy? 10 Under $1 To Watch This Week
Penny stocks to buy for under $1 but are they worth the risk? The post Best Penny Stocks To Buy?
2022-12-23 12:45:52 - PennyStocks
Best Penny Stocks To Buy? 6 Under $1 To Watch Now
2022-10-17 13:33:25 - Zacks Investment Research
NeuBase (NBSE) Up on Restructuring Plan, Set to Lower Workforce
NeuBase (NBSE) intends to reduce its existing workforce by nearly 60%. The company plans to maximize shareholder value and focus on the advancement of its platform in gene editing.